David Habiger Acquires 2,100 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Boston Scientific Price Performance

Shares of BSX stock opened at $49.35 on Friday. The firm has a market cap of $71.53 billion, a price-to-earnings ratio of 19.98, a PEG ratio of 1.08 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average price of $45.75 and a 200 day moving average price of $60.73.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the business. Kelleher Financial Advisors acquired a new position in Boston Scientific in the second quarter valued at about $25,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at approximately $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on BSX. BTIG Research lowered their target price on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Robert W. Baird set a $56.00 price target on Boston Scientific in a research report on Thursday, July 30th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Finally, Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.